Release Date
Geography
Language of Resource
Full Text Available
Open Access / OK to Reproduce
Peer Reviewed
Objective
To assess the effectiveness and cost-effectiveness of office-based buprenorphine treatment (OBBT) in the U.S., in terms of fatal and nonfatal overdoses and deaths over five years, discounted lifetime quality-adjusted life years (QALYs), and costs.
Findings/Key points
Using a limited societal perspective that additionally includes patient costs and criminal justice costs, OBBT is cost-saving compared to no treatment even under pessimistic assumptions about efficacy and cost. Expansion of OBBT would be highly cost-effective compared to no treatment when considered from a healthcare perspective, and cost-saving when reduced criminal justice costs are included.
Design/methods
We performed a model-based analysis of buprenorphine treatment provided in a primary care setting for the U.S. population with OUD.
